基蛋生物
(603387)
| 流通市值：49.45亿 | | | 总市值：49.45亿 |
| 流通股本：5.07亿 | | | 总股本：5.07亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 267,501,249.08 | 1,051,714,310.24 | 757,689,168.63 | 512,692,328.58 |
| 营业收入 | 267,501,249.08 | 1,051,714,310.24 | 757,689,168.63 | 512,692,328.58 |
| 二、营业总成本 | 192,223,993.5 | 797,401,359.97 | 598,836,358.03 | 392,555,381.53 |
| 营业成本 | 79,333,175.66 | 317,725,137.15 | 235,440,545.68 | 157,113,429.07 |
| 税金及附加 | 3,325,045.63 | 13,376,651.9 | 9,482,420.06 | 6,415,797.25 |
| 销售费用 | 48,704,689.71 | 231,075,291.94 | 173,218,899.03 | 112,129,453.99 |
| 管理费用 | 22,143,668.01 | 91,370,201.47 | 68,136,347.78 | 44,398,492.48 |
| 研发费用 | 41,352,138.53 | 157,404,097.24 | 126,407,694.99 | 83,489,962.28 |
| 财务费用 | -2,634,724.04 | -13,550,019.73 | -13,849,549.51 | -10,991,753.54 |
| 其中:利息费用 | 2,460,046.19 | 12,089,166.52 | 9,101,233.58 | 6,272,979.72 |
| 其中:利息收入 | 7,575,531.9 | 33,085,124.21 | 26,403,077.91 | 18,040,727.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 5,135,485.63 | 27,002,141.94 | 21,665,404.59 | 15,721,758.28 |
| 加:投资收益 | -643,155.49 | -8,710,147.94 | 7,110,591.15 | 1,545,195.32 |
| 资产处置收益 | 191,119.01 | -47,740.64 | -145,060.54 | -589,649.32 |
| 资产减值损失(新) | -1,463,175.42 | -28,682,414.8 | 3,086,308.36 | -3,429,714.9 |
| 信用减值损失(新) | -8,326,929.52 | -29,099,804.56 | -34,129,475.78 | -25,040,610.96 |
| 其他收益 | 11,031,470.75 | 16,244,938.72 | 10,085,271.15 | 5,067,825.12 |
| 四、营业利润 | 81,202,070.54 | 231,019,922.99 | 166,525,849.53 | 113,411,750.59 |
| 加:营业外收入 | 50 | 1,922,589.61 | 340.58 | 12,964.54 |
| 减:营业外支出 | 314,042.98 | 5,250,975.98 | 3,350,889.47 | 2,899,197.72 |
| 五、利润总额 | 80,888,077.56 | 227,691,536.62 | 163,175,300.64 | 110,525,517.41 |
| 减:所得税费用 | 7,647,818.71 | 15,771,136.96 | 12,980,322.04 | 7,746,725.45 |
| 六、净利润 | 73,240,258.85 | 211,920,399.66 | 150,194,978.6 | 102,778,791.96 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 73,240,258.85 | 211,920,399.66 | 150,194,978.6 | 102,778,791.96 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 76,303,243.95 | 220,661,381.93 | 160,543,807.13 | 108,808,763.23 |
| 少数股东损益 | -3,062,985.1 | -8,740,982.27 | -10,348,828.53 | -6,029,971.27 |
| 扣除非经常损益后的净利润 | 65,836,884.88 | 183,936,000.17 | 134,531,634 | 93,228,621.81 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.44 | 0.32 | 0.21 |
| (二)稀释每股收益 | 0.15 | 0.44 | 0.32 | 0.21 |
| 八、其他综合收益 | -239,372.51 | -325,162.65 | -141,750.76 | -23,895.45 |
| 归属于母公司股东的其他综合收益 | -239,372.51 | -325,162.65 | -141,750.76 | -23,895.45 |
| 九、综合收益总额 | 73,000,886.34 | 211,595,237.01 | 150,053,227.84 | 102,754,896.51 |
| 归属于母公司股东的综合收益总额 | 76,063,871.44 | 220,336,219.28 | 160,402,056.37 | 108,784,867.78 |
| 归属于少数股东的综合收益总额 | -3,062,985.1 | -8,740,982.27 | -10,348,828.53 | -6,029,971.27 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |